Status:
COMPLETED
Effect of Butorphanol on Colonoscopy for Patients With Postoperative Visceral Pain
Lead Sponsor:
Beijing Tiantan Hospital
Conditions:
Colonoscopy
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The total incidence of abdominal pain after colonoscopy is almost 50%. Butorphanol is a mixed opioid receptor agonist-antagonist, which has strong sedative and analgesic effects. This clinical study a...
Eligibility Criteria
Inclusion
- ASA status I-11
- patients performing colonoscopy
- sign the informed consent
Exclusion
- BMI\>30, pregnant
- diabetes
- depression
- patients dependent on opioids
- hypertension poorly controlled
- serious complications of important organs
- obvious abdominal pain before colonoscopy
Key Trial Info
Start Date :
August 14 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2021
Estimated Enrollment :
203 Patients enrolled
Trial Details
Trial ID
NCT04477733
Start Date
August 14 2020
End Date
September 30 2021
Last Update
February 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tiantan Hospital
Beijing, China, 100070